Comparative efficacy of intravenous levetiracetam and phenytoin in status epilepticus: a systematic review and meta-analysis of randomized controlled trials

Keywords: levetiracetam, phenytoin, status epilepticus
Abstract viewed: 550 times
PDF downloaded: 0 times
HTML downloaded: 0 times
EPUB downloaded: 0 times
Supplementary File downloaded: 0 times

Abstract

BACKGROUND Status epilepticus (SE) is a neurological emergency, with the current guidelines for second-line anticonvulsants may include phenytoin, levetiracetam, valproic acid, and phenobarbital. However, some studies suggest that levetiracetam may be better at stopping seizures in SE. This study aimed to compare the efficacy of intravenous (IV) levetiracetam and phenytoin in SE.

METHODS We searched PubMed, ScienceDirect, Cochrane, and Google Scholar for randomized controlled trials (RCTs) on administering IV levetiracetam or phenytoin in patients with SE. RCTs were screened using eligibility criteria, and their quality was assessed using the Cochrane risk of bias tool. Heterogeneity was assessed using the I² test, and publication bias was evaluated using Egger’s test. All analyses were performed using Review Manager version 5.4 (The Cochrane Collaboration, UK) and Stata 17 (StataCorp LLC, USA).

RESULTS 12 RCTs involving 2,137 patients (1,099 receiving levetiracetam) met the inclusion criteria. Pooled analysis showed that levetiracetam therapy had a significantly higher rate of seizure cessation than phenytoin (RR: 1.10, 95% CI = 1.05−1.14, p = 0.02, I² = 51%). Less adverse events were observed in the levetiracetam group (9.34%) than in the phenytoin group (11.62%; RR: 0.82, 95% CI = 0.66–1.02, p = 0.07). However, there was no significant difference regarding IV levetiracetam or phenytoin administration with the incidence of admission to critical care (RR: 1.01; 95% CI = 0.93–1.10, p = 0.80) and mortality (RR: 1.08; 95% CI = 0.54–2.15; p = 0.82).

CONCLUSIONS IV levetiracetam was significantly better in the cessation of seizures in SE patients than phenytoin.

Downloads

Download data is not yet available.

References

  1. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615-24. https://doi.org/10.1016/S1474-4422(15)00042-3

  2. Pichler M, Hocker S. Management of status epilepticus. Handb Clin Neurol. 2017;140:131-51. https://doi.org/10.1016/B978-0-444-63600-3.00009-X

  3. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23. https://doi.org/10.1007/s12028-012-9695-z

  4. Dell'Aquila J, Soti V. Treating status epilepticus: phenytoin versus levetiracetam. Cureus. 2021;13(10):e18515. https://doi.org/10.7759/cureus.18515

  5. Parums DV. Editorial: review articles, systematic reviews, meta-analysis, and the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines. Med Sci Monit. 2021;27:e934475. https://doi.org/10.12659/MSM.934475

  6. Appleton RE, Rainford NE, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. Health Technol Assess. 2020;24(58):1-96. https://doi.org/10.3310/hta24580

  7. Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959-63. https://doi.org/10.1016/j.jocn.2014.12.013

  8. Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217-24. Erratum in: Lancet. 2023;401(10387):1498.

  9. Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019;393(10186):2135-45. https://doi.org/10.1016/S0140-6736(19)30722-6

  10. Gujjar AR, Nandhagopal R, Jacob PC, Al-Hashim A, Al-Amrani K, Ganguly SS, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure. 2017;49:8-12. https://doi.org/10.1016/j.seizure.2017.05.001

  11. Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--pilot study. Epilepsy Res. 2015;114:52-8. https://doi.org/10.1016/j.eplepsyres.2015.04.013

  12. Nakamura K, Marushima A, Takahashi Y, Mochizuki M, Kimura A, Fukuda Y, et al. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial. J Neurol Neurosurg Psychiatry. 2023;94(1):42-8. https://doi.org/10.1136/jnnp-2022-329485

  13. Nalisetty S, Kandasamy S, Sridharan B, Vijayakumar V, Sangaralingam T, Krishnamoorthi N. Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus. Indian J Pediatr. 2020;87(7):512-9. https://doi.org/10.1007/s12098-020-03221-2

  14. Nazir M, Tarray RA, Asimi R, Syed WA. Comparative efficacy of IV phenytoin, IV valproate, and IV levetiracetam in childhood status epilepticus. J Epilepsy Res. 2020;10(2):69-73. https://doi.org/10.14581/jer.20011

  15. Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, et al. Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial. J Clin Neurol. 2019;15(4):468-72. https://doi.org/10.3988/jcn.2019.15.4.468

  16. Vignesh V, Rameshkumar R, Mahadevan S. Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial. Indian Pediatr. 2020;57(3):222-7. https://doi.org/10.1007/s13312-020-1755-4

  17. Wani G, Imran A, Dhawan N, Gupta A, Giri JI. Levetiracetam versus phenytoin in children with status epilepticus. J Family Med Prim Care. 2019;8(10):3367-71. https://doi.org/10.4103/jfmpc.jfmpc_750_19

  18. Shi R, Yin HQ, Wang ZZ. [Efficacy and safety of levetiracetam versus phenytoin as second-line drugs for the treatment of children with convulsive status epilepticus: a meta analysis]. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(4):356-62. Chinese.

  19. Xue T, Wei L, Shen X, Wang Z, Chen Z, Wang Z. Levetiracetam versus phenytoin for the pharmacotherapy of benzodiazepine-refractory status epilepticus: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2020;34(12):1205-15. https://doi.org/10.1007/s40263-020-00770-0

  20. Li L, Zhang Y, Jia L, Jia D, Faramand A, Chong W, et al. Levetiracetam versus phenytoin for the treatment of established status epilepticus: a systematic review and meta-analysis of randomized controlled trials. Seizure. 2020;78:43-8. https://doi.org/10.1016/j.seizure.2020.03.002

  21. Feng Y, Chen Y, Jia Y, Wang Z, Wang X, Jiang L, et al. Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. Seizure. 2021;91:339-45. https://doi.org/10.1016/j.seizure.2021.07.012

  22. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-23. https://doi.org/10.1111/epi.13121

  23. Chu SS, Wang HJ, Zhu LN, Xu D, Wang XP, Liu L. Therapeutic effect of intravenous levetiracetam in status epilepticus: a meta-analysis and systematic review. Seizure. 2020;74:49-55. https://doi.org/10.1016/j.seizure.2019.11.007

  24. Contreras-García IJ, Cárdenas-Rodríguez N, Romo-Mancillas A, Bandala C, Zamudio SR, Gómez-Manzo S, et al. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022;15(4):475. https://doi.org/10.3390/ph15040475

  25. Weinstock A, Ruiz M, Gerard D, Toublanc N, Stockis A, Farooq O, et al. Prospective open-label, single-arm, multicenter, safety, tolerability, and pharmacokinetic studies of intravenous levetiracetam in children with epilepsy. J Child Neurol. 2013;28(11):1423-9. https://doi.org/10.1177/0883073813480241

  26. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003;54(2-3):153-61. Erratum in: Epilepsy Res. 2003;56(2-3):209-10. https://doi.org/10.1016/j.eplepsyres.2003.09.001

  27. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-24. https://doi.org/10.2165/00003088-200443110-00002

Published
2023-07-18
How to Cite
1.
Tasya GA, Djatmiko NI, Rahman FHF, Rahmawati VK. Comparative efficacy of intravenous levetiracetam and phenytoin in status epilepticus: a systematic review and meta-analysis of randomized controlled trials. Med J Indones [Internet]. 2023Jul.18 [cited 2024Jun.16];32(1):45-1. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/6685
Section
Clinical Research